Analyst Consensus ?
ConsensusBuy44 ratings
Bullish3988.6%
Neutral511.4%
Bearish00.0%
Boston Scientific Corporation · BSX · FY2026 Q1 · Calendar Q2 2026
Boston Scientific Beats Q1 but Lowers Full-Year Guidance on EP and WATCHMAN Headwinds
Boston Scientific delivered Q1 FY2026 results that beat on both lines: 9.4% organic revenue growth and adjusted EPS of $0.80 versus $0.79 consensus. However, the stock's trajectory has been defined by the guidance reduction that accompanied those results. Management lowered full-year organic growth to 6.5%-8% and adjusted EPS to $3.34-$3.41, citing unexpected headwinds in electrophysiology, WATCHMAN, and urology. Shares initially rose approximately 9% on the earnings day but subsequently drifted about 13% lower, trading at $45.38 as of July 29, 2026, a 40% discount to the $75.45 analyst consensus target. The dislocation reflects unresolved concerns about the sustainability of EP growth amid intensifying PFA competition from Medtronic, J&J, and Abbott, WATCHMAN volume softness, urology underperformance, and integration risk from the pending Penumbra acquisition. Core growth drivers…
Reported Before market openNYSEHealthcare
$68.46B market cap
90quality score
Company context
Snapshot as of publicationBoston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities.…
Earnings scorecard
Reported versus consensus
Reported EPS
$0.80
Consensus $1
EPS surprise
+1.5%
Reported versus consensus
Reported revenue
$5.20B
Consensus $5.17B
Revenue surprise
+0.6%
Reported versus consensus
Earnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$46.78Current
$48Low
$79.46Average
$130High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Jul 29, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Oppenheimer | Outperform | Outperform | Maintain | Jul 27, 2026 |
| Truist Securities | Buy | Buy | Maintain | Jul 16, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Jul 15, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Jul 13, 2026 |
| Needham | Buy | Buy | Maintain | Jul 8, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Jul 6, 2026 |
| Stifel | Buy | Buy | Maintain | Jun 25, 2026 |
| Jefferies | Buy | Buy | Maintain | Jun 24, 2026 |
| BTIG | Buy | Buy | Maintain | Jun 16, 2026 |
| Canaccord Genuity | Buy | Buy | Maintain | Jun 1, 2026 |
| Wolfe Research | Peer Perform | Outperform | Downgrade | May 29, 2026 |
| Wells Fargo | Equal Weight | Overweight | Downgrade | May 28, 2026 |
| Leerink Partners | Outperform | Outperform | Maintain | May 28, 2026 |
| Citigroup | Buy | Buy | Maintain | May 28, 2026 |
| Barclays | Overweight | Overweight | Maintain | May 28, 2026 |
| Baird | Outperform | Outperform | Maintain | May 19, 2026 |
| B of A Securities | Buy | Buy | Maintain | May 18, 2026 |
| Goldman Sachs | Buy | Buy | Maintain | Apr 23, 2026 |
| Raymond James | Outperform | Strong Buy | Downgrade | Mar 30, 2026 |
| UBS | Buy | Buy | Maintain | Mar 17, 2026 |
| TD Cowen | Buy | Buy | Maintain | Feb 5, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Feb 5, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Feb 5, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Feb 3, 2025 |
| Bernstein | Outperform | Outperform | Maintain | Oct 24, 2024 |
| Deutsche Bank | Hold | Hold | Maintain | Jul 25, 2024 |
| Argus Research | Buy | Buy | Maintain | May 28, 2024 |
| SVB Leerink | Market Perform | Market Perform | Maintain | Apr 28, 2022 |
| Credit Suisse | Outperform | Outperform | Maintain | Jul 28, 2021 |
| SunTrust Robinson Humphrey | Buy | Buy | Maintain | Apr 23, 2020 |
| Stephens & Co. | Overweight | Overweight | Maintain | Mar 26, 2020 |
| CFRA | Strong Buy | Buy | Upgrade | Mar 9, 2020 |
| Cowen & Co. | Outperform | Outperform | Maintain | Dec 30, 2019 |
| Argus | Buy | Buy | Maintain | Oct 26, 2018 |
| Leerink Swann | Outperform | Outperform | Maintain | Apr 26, 2018 |
| Bank of America | Buy | Buy | Maintain | Apr 5, 2018 |
| BTIG Research | Buy | Neutral | Upgrade | Nov 30, 2017 |
| BMO Capital | Outperform | Outperform | Maintain | Oct 27, 2017 |
| Stifel Nicolaus | Buy | Buy | Maintain | Jul 24, 2015 |
| JMP Securities | Market Outperform | Market Outperform | Maintain | Feb 4, 2015 |
| Benchmark | Buy | Hold | Upgrade | Oct 22, 2014 |
| PiperJaffray | Overweight | Neutral | Upgrade | Jan 21, 2014 |
| CL King | Neutral | Strong Buy | Downgrade | Sep 10, 2013 |
| S&P Capital IQ | Buy | Hold | Upgrade | Jun 28, 2013 |
Named analyst price targets
Upside is calculated against the persisted current price $46.78. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| UBS | Analyst unavailable | $74 | $45.51 | +58.2% | Jul 28, 2026 |
| Oppenheimer | Analyst unavailable | $85 | $45.88 | +81.7% | Jul 27, 2026 |
| Truist Financial | Analyst unavailable | $62 | $44.6 | +32.5% | Jul 16, 2026 |
| Mizuho Securities | Anthony Petrone | $70 | $42.63 | +49.6% | Jul 15, 2026 |
| RBC Capital | Shagun Singh | $85 | $44.72 | +81.7% | Jul 13, 2026 |
| Needham | Mike Matson | $57 | $45.3 | +21.8% | Jul 8, 2026 |
| Evercore ISI | Analyst unavailable | $65 | $44.55 | +38.9% | Jul 6, 2026 |
| Stifel Nicolaus | Analyst unavailable | $65 | $44.46 | +38.9% | Jun 25, 2026 |
| Piper Sandler | Analyst unavailable | $65 | $47.17 | +38.9% | Jun 12, 2026 |
| Truist Financial | Analyst unavailable | $64 | $49.34 | +36.8% | Jun 4, 2026 |
| BTIG | Marie Thibault | $65 | $47.68 | +38.9% | Jun 2, 2026 |
| Canaccord Genuity | Analyst unavailable | $70 | $48.31 | +49.6% | Jun 1, 2026 |
| Goldman Sachs | Analyst unavailable | $71 | $50.46 | +51.8% | May 28, 2026 |
| Robert W. Baird | Analyst unavailable | $70 | $50.46 | +49.6% | May 28, 2026 |
| Leerink Partners | Mike Kratky | $74 | $50.46 | +58.2% | May 28, 2026 |
| Barclays | Analyst unavailable | $89 | $50.46 | +90.3% | May 28, 2026 |
| Wells Fargo | Larry Biegelsen | $55 | $50.46 | +17.6% | May 28, 2026 |
| Stifel Nicolaus | Rick Wise | $75 | $51.07 | +60.3% | May 27, 2026 |
| Robert W. Baird | Analyst unavailable | $75 | $55.92 | +60.3% | May 19, 2026 |
| Daiwa | Analyst unavailable | $60 | $58.45 | +28.3% | Apr 29, 2026 |
| RBC Capital | Analyst unavailable | $100 | $65.8 | +113.8% | Apr 23, 2026 |
| Oppenheimer | Analyst unavailable | $90 | $65.72 | +92.4% | Apr 23, 2026 |
| Canaccord Genuity | William Plovanic | $71 | $64.87 | +51.8% | Apr 23, 2026 |
| Needham | Mike Matson | $77 | $64.87 | +64.6% | Apr 23, 2026 |
| Truist Financial | Analyst unavailable | $85 | $64.87 | +81.7% | Apr 23, 2026 |
| Robert W. Baird | Analyst unavailable | $78 | $64.87 | +66.7% | Apr 23, 2026 |
| Wells Fargo | Analyst unavailable | $75 | $64.87 | +60.3% | Apr 23, 2026 |
| Barclays | Matt Miksic | $96 | $64.87 | +105.2% | Apr 23, 2026 |
| Goldman Sachs | David Roman | $84 | $64.87 | +79.6% | Apr 22, 2026 |
| Jefferies | Matthew Taylor | $100 | $64.87 | +113.8% | Apr 22, 2026 |
| Stifel Nicolaus | Rick Wise | $85 | $60.99 | +81.7% | Apr 21, 2026 |
| Truist Financial | Analyst unavailable | $90 | $64.92 | +92.4% | Apr 15, 2026 |
| Mizuho Securities | Analyst unavailable | $90 | $62.06 | +92.4% | Apr 13, 2026 |
| Goldman Sachs | Analyst unavailable | $93 | $70.17 | +98.8% | Mar 26, 2026 |
| Canaccord Genuity | William Plovanic | $109 | $74.73 | +133.0% | Feb 17, 2026 |
| Bernstein | Lee Hambright | $112 | $77.46 | +139.4% | Feb 6, 2026 |
| Truist Financial | Analyst unavailable | $95 | $77.02 | +103.1% | Feb 5, 2026 |
| RBC Capital | Analyst unavailable | $115 | $77.16 | +145.8% | Feb 5, 2026 |
| Needham | Analyst unavailable | $97 | $75.52 | +107.4% | Feb 5, 2026 |
| Mizuho Securities | Analyst unavailable | $115 | $75.29 | +145.8% | Feb 5, 2026 |
| Evercore ISI | Analyst unavailable | $96 | $75.64 | +105.2% | Feb 5, 2026 |
| Wells Fargo | Analyst unavailable | $94 | $75.5 | +100.9% | Feb 5, 2026 |
| Goldman Sachs | Analyst unavailable | $99 | $75.5 | +111.6% | Feb 5, 2026 |
| Robert W. Baird | Analyst unavailable | $101 | $75.5 | +115.9% | Feb 5, 2026 |
| UBS | Analyst unavailable | $120 | $75.5 | +156.5% | Feb 5, 2026 |
| Canaccord Genuity | William Plovanic | $112 | $75.5 | +139.4% | Feb 5, 2026 |
| Stifel Nicolaus | Rick Wise | $110 | $75.5 | +135.1% | Feb 4, 2026 |
| BTIG | Analyst unavailable | $110 | $75.61 | +135.1% | Feb 4, 2026 |
| Barclays | Analyst unavailable | $124 | $91.87 | +165.1% | Feb 3, 2026 |
| National Bank | Analyst unavailable | $115 | $93.13 | +145.8% | Feb 2, 2026 |
| Oppenheimer | Analyst unavailable | $100 | $90.03 | +113.8% | Jan 16, 2026 |
| Goldman Sachs | David Roman | $112 | $98.38 | +139.4% | Jan 9, 2026 |
| Evercore ISI | Analyst unavailable | $112 | $95.15 | +139.4% | Jan 5, 2026 |
| Truist Financial | Analyst unavailable | $120 | $96.56 | +156.5% | Dec 18, 2025 |
| RBC Capital | Analyst unavailable | $130 | $92.95 | +177.9% | Dec 17, 2025 |
| Canaccord Genuity | William Plovanic | $131 | $92.95 | +180.0% | Dec 17, 2025 |
| Truist Financial | Analyst unavailable | $130 | $103.52 | +177.9% | Oct 23, 2025 |
| Morgan Stanley | Patrick Wood | $130 | $103.85 | +177.9% | Oct 23, 2025 |
| UBS | Analyst unavailable | $140 | $104.24 | +199.3% | Oct 23, 2025 |
| Wells Fargo | Analyst unavailable | $125 | $104.24 | +167.2% | Oct 23, 2025 |
| Goldman Sachs | Analyst unavailable | $124 | $103.85 | +165.1% | Oct 22, 2025 |
| Evercore ISI | Analyst unavailable | $110 | $96.7 | +135.1% | Oct 7, 2025 |
| Barclays | Analyst unavailable | $136 | $95.85 | +190.7% | Oct 2, 2025 |
| Truist Financial | Richard Newitter | $129 | $94.15 | +175.8% | Oct 1, 2025 |
| BTIG | Analyst unavailable | $132 | $97.63 | +182.2% | Oct 1, 2025 |
| Robert W. Baird | Analyst unavailable | $128 | $97.63 | +173.6% | Oct 1, 2025 |
| Canaccord Genuity | Analyst unavailable | $132 | $97.63 | +182.2% | Oct 1, 2025 |
| Oppenheimer | Suraj Kalia | $125 | $108.14 | +167.2% | Sep 8, 2025 |
| Raymond James | Jayson Bedford | $121 | $103.8 | +158.7% | Jul 21, 2025 |
| Leerink Partners | Mike Kratky | $118 | $101.49 | +152.2% | Jun 16, 2025 |
| Truist Financial | Richard Newitter | $117 | $100.55 | +150.1% | Apr 24, 2025 |
| BTIG | Marie Thibault | $124 | $98.87 | +165.1% | Apr 23, 2025 |
| Argus Research | Analyst unavailable | $130 | $105.35 | +177.9% | Feb 18, 2025 |
| Piper Sandler | Matt O'Brien | $115 | $103.07 | +145.8% | Feb 3, 2025 |
| Evercore ISI | Vijay Kumar | $100 | $89.38 | +113.8% | Jan 2, 2025 |
| BTIG | Marie Thibault | $101 | $89.68 | +115.9% | Dec 30, 2024 |
| RBC Capital | Shagun Singh | $98 | $87.45 | +109.5% | Oct 24, 2024 |
| C.L. King | Kristen Stewart | $90 | $87.45 | +92.4% | Oct 24, 2024 |
| Canaccord Genuity | William Plovanic | $98 | $88.07 | +109.5% | Oct 21, 2024 |
| Stifel Nicolaus | Rick Wise | $100 | $86.42 | +113.8% | Oct 18, 2024 |
| Robert W. Baird | David Rescott | $100 | $87.55 | +113.8% | Oct 15, 2024 |
| Truist Financial | Richard Newitter | $100 | $87.2 | +113.8% | Oct 14, 2024 |
| Piper Sandler | Matt O'Brien | $90 | $84.22 | +92.4% | Sep 19, 2024 |
| Deutsche Bank | Pito Chickering | $78 | $78.11 | +66.7% | Jul 25, 2024 |
| BTIG | Marie Thibault | $84 | $77.69 | +79.6% | Jul 15, 2024 |
| Canaccord Genuity | William Plovanic | $83 | $76.31 | +77.4% | Jun 18, 2024 |
| Robert W. Baird | David Rescott | $90 | $77.42 | +92.4% | Jun 11, 2024 |
| Goldman Sachs | David Roman | $90 | $74.98 | +92.4% | May 30, 2024 |
| Argus Research | John Eade | $95 | $75.63 | +103.1% | May 28, 2024 |
| Oppenheimer | Steven Lichtman | $77 | $73.27 | +64.6% | Apr 25, 2024 |
| Evercore ISI | Vijay Kumar | $78 | $72.91 | +66.7% | Apr 25, 2024 |
| RBC Capital | Shagun Singh | $82 | $72.91 | +75.3% | Apr 25, 2024 |
| Mizuho Securities | Anthony Petrone | $85 | $72.91 | +81.7% | Apr 25, 2024 |
| Robert W. Baird | David Rescott | $84 | $72.91 | +79.6% | Apr 25, 2024 |
| Truist Financial | Richard Newitter | $86 | $72.91 | +83.8% | Apr 25, 2024 |
| Wells Fargo | Lawrence Biegelsen | $82 | $72.91 | +75.3% | Apr 25, 2024 |
| Deutsche Bank | Pito Chickering | $73 | $72.91 | +56.0% | Apr 24, 2024 |
| BTIG | Marie Thibault | $80 | $72.91 | +71.0% | Apr 24, 2024 |
| Stifel Nicolaus | Rick Wise | $83 | $72.91 | +77.4% | Apr 24, 2024 |
| BTIG | Marie Thibault | $74 | $68.07 | +58.2% | Apr 15, 2024 |
| Argus Research | John Eade | $80 | $67.45 | +71.0% | Apr 3, 2024 |
| Mizuho Securities | Anthony Petrone | $80 | $64.82 | +71.0% | Feb 1, 2024 |
| J.P. Morgan | Analyst unavailable | $55 | $47.31 | +17.6% | Feb 2, 2023 |
| Needham | Analyst unavailable | $53 | $47.54 | +13.3% | Feb 2, 2023 |
| Morgan Stanley | Analyst unavailable | $56 | $46.18 | +19.7% | Jan 6, 2023 |
| Mizuho Securities | Anthony Petrone | $52 | $46.08 | +11.2% | Dec 22, 2022 |
| Truist Financial | Analyst unavailable | $54 | $45.64 | +15.4% | Dec 20, 2022 |
| Raymond James | Analyst unavailable | $54 | $45.63 | +15.4% | Dec 8, 2022 |
| Raymond James | Analyst unavailable | $48 | $40.83 | +2.6% | Jul 28, 2022 |
| BTIG | Analyst unavailable | $50 | $40.31 | +6.9% | Jul 28, 2022 |
| Truist Financial | Analyst unavailable | $45 | $37.44 | -3.8% | Jul 20, 2022 |
| Canaccord Genuity | Analyst unavailable | $43 | $37.76 | -8.1% | Jun 29, 2022 |
| BTIG | Analyst unavailable | $45 | $37.1 | -3.8% | Jun 24, 2022 |
| Piper Sandler | Matt O’Brien | $50 | $42.11 | +6.9% | Apr 30, 2022 |
| Raymond James | Analyst unavailable | $50 | $43 | +6.9% | Apr 28, 2022 |
| Leerink Partners | Analyst unavailable | $48 | $43.06 | +2.6% | Apr 28, 2022 |
| Bank of America Securities | Travis Steed | $55 | $43.96 | +17.6% | Mar 3, 2022 |
| Cowen & Co. | Josh Jennings | $50 | $41.44 | +6.9% | Feb 2, 2022 |
| BTIG | Marie Thibault | $52 | $41.44 | +11.2% | Feb 2, 2022 |
| Macquarie | Luke McFarlane | $51 | $41.28 | +9.0% | Dec 9, 2021 |
| Canaccord Genuity | William Plovanic | $51 | $43.24 | +9.0% | Oct 28, 2021 |
| UBS | Brent Dilts | $118 | $43.24 | +152.2% | Oct 28, 2021 |
| Piper Sandler | Matthew O'Brien | $51 | $43.73 | +9.0% | Oct 27, 2021 |
| Credit Suisse | Matt Miksic | $54 | $45 | +15.4% | Sep 23, 2021 |
| Jefferies | Anthony Petrone | $55 | $44.31 | +17.6% | Sep 22, 2021 |
| Argus Research | John Eade | $132 | $45.88 | +182.2% | Aug 2, 2021 |
| Wells Fargo | Larry Biegelsen | $52.5 | $45.88 | +12.2% | Aug 1, 2021 |
| Stifel Nicolaus | Rick Wise | $50 | $45.51 | +6.9% | Jul 27, 2021 |
| Goldman Sachs | Amit Hazan | $50 | $42.74 | +6.9% | Jul 14, 2021 |
| Stephens | Chris Cooley | $52 | $44.1 | +11.2% | Apr 29, 2021 |
| Oppenheimer | Steven Lichtman | $47 | $44.24 | +0.5% | Apr 28, 2021 |
| Citigroup | Joanne Wuensch | $51 | $44.24 | +9.0% | Apr 28, 2021 |
Track every rating change on BSX the moment it posts. Free to start.
Start freeMarket reaction
prior-close to event-session close
Stock move
+9.0%
Event window
SPY move
+1.0%
Same window
Abnormal move
+8.0%
Stock minus SPY
Volume
2.4×
Versus trailing sessions
Subsequent drift
-12.6%
Up to 20 sessions
BSXSPY benchmark
Follow BSX with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeTranscript intelligence
What changed
In Q1 FY2026, BSX delivered 9.4% organic revenue growth and adjusted EPS of $0.80, a 1.5% beat over the $0.79 consensus. Revenue of $5.20B exceeded estimates by 0.6%. The most significant change was the reduction in full-year guidance: organic growth was lowered to 6.5%-8% and adjusted EPS to $3.34-$3.41, driven by unexpected softness in electrophysiology, the WATCHMAN portfolio, and urology (only 1% organic growth). Management also announced the closure of the Valencia Technologies acquisition and confirmed a $2B share repurchase plan for Q2 within the $5B total program, even as the Penumbra acquisition awaits a shareholder vote. The stock surged roughly 9% on the earnings day but has since drifted approximately 13% lower, with the shares now trading at $45.38 versus the $75.45 analyst consensus target.
Guidance delta
Full-year organic revenue growth guidance was lowered to 6.5%-8% and adjusted EPS guidance was reduced to $3.34-$3.41. The guidance cut reflects three specific headwinds: (1) unexpected deceleration in electrophysiology, partly tied to the accelerated discontinuation of the POLARx cryoablation system following safety events; (2) WATCHMAN volume trends falling below expectations; and (3) urology weakness with only 1% organic growth, prompting new product launches and commercial hiring.
Key takeaways
- Q1 organic revenue grew 9.4% and adjusted EPS of $0.80 beat the $0.79 consensus by 1.5%.
- Full-year guidance was lowered to 6.5%-8% organic growth and $3.34-$3.41 adjusted EPS, citing EP, WATCHMAN, and urology headwinds.
- FARAPULSE PFA, WATCHMAN, and OPAL mapping portfolio continue to drive growth, particularly in the U.S. and APAC.
- Urology lagged at 1% organic growth, prompting new product launches including StoneSmart and commercial hiring.
- Valencia Technologies acquisition closed; Penumbra acquisition pending shareholder vote on May 7.
- Company plans $2B in share repurchases in Q2 within a $5B total buyback program.
Management priorities
- Launch third-generation FARAPULSE platform and FARAWAVE Ultra in H1 2027.
- Initiate IDE for FANAFLEX later this year with U.S. launch planned for 2028.
- Scale Seismic IVL for above- and below-knee applications in 2027.
- Roll out additional urology products including StoneSmart ecosystem and insulin urethroscope.
- Increase commercial investment for WATCHMAN and EP, and pursue further tuck-in acquisitions.
- Execute $2B share repurchase in Q2 while maintaining the $5B overall buyback program.
Related earnings events
HealthcareSources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-07-29T14:35:15.413083+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-29T14:35:15.411461+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.